Portable AI Chest X-Ray Triage Is Emerging as a Global Screening Market
Morningstar says the AI portable chest x-ray triage device market could reach $900 million by 2036, driven by tuberculosis screening expansion and point-of-care diagnostics. The forecast points to one of AI imaging's most compelling public-health use cases: low-cost triage in settings where radiology capacity is scarce.
This forecast is a reminder that some of the most important AI imaging markets will be built outside tertiary hospitals. Portable chest x-ray triage is especially relevant in tuberculosis screening, where speed, access, and cost often matter more than sophisticated downstream analytics.
The appeal is straightforward: AI can help prioritize abnormal studies, support overburdened clinicians, and extend screening into settings that lack expert readers. That makes the technology useful not only in wealthy health systems, but also in community clinics, mobile units, and national TB programs that need scalable triage tools.
Still, projected market size should not be confused with clinical inevitability. Adoption will depend on regulatory acceptance, reimbursement pathways, device durability, and proof that AI improves real-world outcomes rather than just detection rates. In public-health use cases, implementation friction can be as decisive as algorithm quality.
What makes this story significant is the direction of travel. Imaging AI is moving from premium specialty workflows into front-line screening infrastructure. If the promise holds, portable AI x-ray systems could become one of the most practical examples of AI delivering measurable access gains rather than merely automation within elite care settings.